Miranda LJM, Sánchez GA, Saavedra SMA, Jara QLJ

Language: Spanish
References: 41
Page: 117-124
PDF size: 218.39 Kb.

ABSTRACT

Objective: our objective was to evaluate the usefulness of urinalysis and 24-h proteinuria as predictor variable for the glomerulonephritis class in patients with systemic lupus erythematosus (SLE), and to correlate specific abnormalities with the different histologic indexes. Material and methods: we included all patients with lupus nephritis (LN) who had renal biopsy between 1985 and 2000. Main outcome measurements were class of LN, and activity, chronicity, and pathologic indexes. Statistical analysis: Chi-squared test was used to compare differences among proportions. One-way ANOVA was used to compare differences among means. Pearson correlation coefficient was use to estimate association among continuous variables. SPSS software version 10.0 for windows was used. Results: one hundred fourteen patients were included (two with class II, 17 with class III, 83 with class IV, and 12 with class V). Abnormal urinalysis showed a trend to predict class IV LN; however, this did not reach statistical significance (1.14 [0.9-1.57]). There were positive correlations between proteinuria and activity index (r = 0.25, p = 0.013), chronicity index (r = 0.3, p = 0.005), and pathologic index (r = 0.3, p = 0.001). Conclusions: abnormal urinalysis is not useful to establish LN class. On the other hand, 24-h proteinuria showed significant correlation with activity, chronicity, and pathologic indexes.

REFERENCES

1. Kashgarian M, Wallace DJ, Hahn BH, Klippel JH. Lupus nephritis. En: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. Textbook. Fifth edition. Williams and Wilkins; 1997. p. 1037-1066.

2. 2. Datta SK. Production of pathogenic antibodies. Cognate interactions between autoimmune T and B cells. Lupus 1998;7(9):585-590.

3. 3. Austin HA. Clinical evaluation and monitoring of lupus kidney disease. Lupus 1998;7(9):618-621.

4. 4. Domoto DT. The significance of electron dense deposits in mild lupus nephritis. Yale J Biol Med 1980;53:317-324.

5. 5. Cameron. Lupus nephritis. J Am Soc Nephrol 1999; 10(2):413-424.

6. 6. Hricik, Chung-Park. Glomerulonephritis. New Engl J Med 1998;339(13):888-898.

7. 7. Golbus J, McCune WJ. Lupus nephritis. Clasifi-cation, prognosis, immunopathogenesis and treat-ment. Rheum Clin North Am 1994;20:213-224.

8. 8. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials. A critical overview. Lupus 1998; 7(9):622-629.

9. 9. Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382-391.

10. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-695.

11. Balow JE, Austin HA. Renal disease in systemic lupus erythematosus. Kidney Disease Section, National Institutes of Health, Bethesda, Maryland. Rheum Dis Clin North Am 1988;14:117-133.

12. Balow JE, Austin HA, Tsokos GC, Antonovych TT, et al. Lupus nephritis. NIH Conference. An Intern Med 1987;106:79-94.

13. Nakashima A. Serological and histological study of lupus nephritis with special reference to anti-SSA antibody. Nippon Jinzo Gakkai Shi 1989;31:743-755.

14. Appel GB, Coehn DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987;83:877-885.

15. Esdaile JM, Federgreen W, Quintal H, et al. Predic-tors of one year outcome in lupus nephritis. The im-portance of renal biopsy. Q J Med 1991;81: 907-918.

16. Rahman P, Gladman DD, Ibáñez D, Urowitz MB. Sig-nificance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus 2001;10:418-423.

17. Fairley KF, Birch DF. Microscopic urianalysis in glomerulonephritis. Kidney Int 1993;44:S9-S12.

18. Herbert LA, Dillon JJ, Middendorf, et al. Rela-tionship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995;26:432-438.

19. Urowitz MB, Gladman DD, Tozman EC, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984;11:783-787.

20. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35:630-640.

21. Donadio JV, et al. Prognosis determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4:109-115.

22. Austin HA, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 pa-tients. Nephrol Dial Transplant 1995;10:1620-1628.

23. Mitjavila F, Pac V, Moga I, et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol 1997;15:625-631.

24. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythe-matosus. Arthritis Rheum 1982;25:1271-1277.

25. Churg J, Bernstein J, Glassock RJ. Lupus nephritis. En: Churg J, Bernstein J, Glassock RJ, editors. Renal diseases classification and atlas of glomerular diseases. New York: Igaku-Shoin; 1995. p. 151.

26. Berden JHM. Lupus nephritis. Kydney Int 1997;52: 538-558.

27. Conlon PJ, Fisher CA, et al. Clinical, biochemical, and pathological predictors of poor response to intra-venous cyclophosphamide in patients with prolife-rative lupus nephritis. Clin Nephrol 1996;46:170-175.

28. Austin HA, Klippel JH, Balow JE, LeRiche NGH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. New Engl J Med 1986;314:614-619.

29. Schwartz MM, Lan SP, Bernstein J, et al. Role of pathology indices in the management of severe lupus glomerulonephritis. Kidney Int 1992;42:743-748.

30. Remuzzi G, Negri M, et al. Gruppo Italiano per lo Studio della Nefrite Lupica (GINSEL). Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after diagnosis. Am J Kidney Dis 1992;19:473-479.

31. Schena FP, Gesualldo L, Grandallano G, Montinaro V. Progression of renal damage in human glomerulo-nephritis: Is there sleight of hand in winning the game? Kidney Int 1997;52:1439-1457.

32. Tanaka H, Akama H, Tominaga N, et al. Progres-sive renal failure in patients with lupus nephritis. J Intern Med 1993;234:257-262.

33. McLaughlin JR, Bombardier C, Farewell VT, et al. Kid-ney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and labo-ratory variables. Arthritis Rheum 1994;37:559-567.

34. Neuman K, Wallace DJ, Azen C, et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Sem Arthritis Rheum 1995;25:47-55.

35. Lim CS, Chin HJ, Jung YC, et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 1999;52:139-147.

36. Nossent HC, Henzen-Logmans SC, Vroom TM, et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 1990;33:970-977.

37. Jacobsen S, Starkilnt H, Petersen J, et al. Prognosis value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol 1999;28:288-299.

38. Hill GS, Delahousse M, Nochy D, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000;58: 1160-1173.

39. Nakamura T, Ushiyama C, Suzuki S, et al. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000;320:112-116.

40. Miranda JM, Prieto RE, Paniagua R, García G, Amato D, Barile L, Jara LJ. Clinical significance of serum and urine prolactin levels in lupus glomerulo-nephritis. Lupus 1998;7:387-91.

41. Miranda JM, García-Torres R, Jara LJ, Medina F, Cervera H, Fraga A. Renal biopsy in systemic lupus erythematosus: significance of glomerular thrombosis. Analysis of 108 cases. Lupus 1994;3: 25-29.